Annexon’s ANX007 Misses GA Endpoint, But May Have Visual Acuity Path Forward
Executive Summary
The ARCHER study did not show improvement in lesion growth, but still showed an improvement in best corrected visual acuity, potentially opening a pathway toward a pivotal trial.
You may also be interested in...
Astellas Paying $5.9bn For Iveric To Boost Ophthalmology Presence
Astellas set to acquire private US firm to add to its strategic capabilities in ophthalmology focus area, along with another revenue pillar as it prepares for Xtandi expiry.
Apellis Set For Blockbuster Success With Syfovre, The First Approved Geographic Atrophy Drug
Around five million people worldwide suffer from geographic atrophy, and Apellis’s drug will be the first to offer hope of slowing the disease’s progress, as it reaches the US market at a price comparable to the VEGF inhibitors.
ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use
The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.